他莫昔芬相关子宫癌之谜揭晓

IF 29 1区生物学 Q1 GENETICS & HEREDITY

Nature genetics Pub Date : 2025-08-27 DOI:10.1038/s41588-025-02316-w

引用次数: 0

摘要

他莫昔芬是治疗乳腺癌的必备药物。与主流的治疗相关肿瘤发生模型不同，他莫昔芬通过直接激活PI3K途径起作用，绕过了散发性子宫癌中最常见的驱动基因突变的需要。这些发现为研究其他药物的类似机制开辟了道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Mystery of tamoxifen-associated uterine cancer uncovered

查看原文本刊更多论文

Mystery of tamoxifen-associated uterine cancer uncovered

Tamoxifen is an essential drug in breast cancer therapy. Unlike prevailing models of therapy-related tumorigenesis, tamoxifen acts by directly activating the PI3K pathway, bypassing the need for mutations in one of the most common driver genes in sporadic uterine cancer. These findings open avenues for investigating similar mechanisms in other drugs.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature genetics 生物-遗传学

CiteScore

43.00

自引率

2.60%

发文量

241

审稿时长

3 months

期刊介绍： Nature Genetics publishes the very highest quality research in genetics. It encompasses genetic and functional genomic studies on human and plant traits and on other model organisms. Current emphasis is on the genetic basis for common and complex diseases and on the functional mechanism, architecture and evolution of gene networks, studied by experimental perturbation. Integrative genetic topics comprise, but are not limited to: -Genes in the pathology of human disease -Molecular analysis of simple and complex genetic traits -Cancer genetics -Agricultural genomics -Developmental genetics -Regulatory variation in gene expression -Strategies and technologies for extracting function from genomic data -Pharmacological genomics -Genome evolution